News | June 09, 2026
Wegovy pill smashes past 3mn prescriptions in under six months in US
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Broadening access for children & patients with inhibitor-complicated hemophilia
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
The session created a platform for meaningful discussions on the challenges of the disease and the importance of timely intervention
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Subscribe To Our Newsletter & Stay Updated
